Loading...
•
Dec 31, 2025
Dianthus Therapeutics Inc Q4 2025 Earnings Report
Net loss widened as R&D spending increased to advance claseprubart and DNTH212 clinical programs.
Key Takeaways
Dianthus Therapeutics reported minimal Q4 2025 revenue while operating expenses increased significantly due to higher research and development activity supporting the advancement of claseprubart and DNTH212 programs, resulting in a larger quarterly net loss.
Total revenue declined to 284000 compared with 1325000 in the prior year quarter.
Net loss widened to 64432000 from 28438000 year-over-year.
Research and development expenses increased significantly to 59895000 reflecting expanded clinical development activity.
Cash, cash equivalents and investments totaled 514400000 providing runway into 2028.
Forward Guidance
Dianthus expects to continue advancing claseprubart and DNTH212 clinical programs, including a Phase 3 trial in generalized Myasthenia Gravis in mid-2026 and multiple clinical data readouts through 2026 while maintaining cash runway into 2028.
Positive Outlook
- GO decision achieved early in Phase 3 CAPTIVATE CIDP trial.
- Phase 3 trial of claseprubart in gMG expected to begin in mid-2026.
- Phase 2 MoMeNtum MMN trial results expected in the second half of 2026.
- Phase 1 DNTH212 data expected in the second half of 2026.
- Cash runway projected to support operations into 2028.
Challenges Ahead
- Quarterly net loss increased significantly year-over-year.
- Operating expenses rose sharply driven by clinical development spending.
- Company currently generates minimal revenue.
- Clinical development timelines remain uncertain.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...